Carolyn Westhoff1, John K Jain, Ian Milsom, Amrit Ray. 1. Department of Obstetrics and Gynecology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA, and Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Göteborg, Sweden. clw3@columbia.edu
Abstract
INTRODUCTION: The study was conducted to assess the impact of depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL (DMPA-SC 104) on body weight. METHODS: Changes in weight from pretreatment were analyzed using data from two 1-year, noncomparative trials of DMPA-SC 104 (North/South American, N=722; European/Asian, N=1065) and a 3-year, randomized study (SC/IM) comparing DMPA-SC 104 (N=266) with the DMPA intramuscular injection 150 mg/mL (DMPA-IM 150). For each study, additional analyses were conducted for changes in body weight by age (<25, 25 to 35 and >35 years) and body mass index (BMI) (<or=25, >25 to <or=30 and >30 kg/m2) subgroups. RESULTS: In both 1-year trials, the mean (+/-SD) weight gain at month 12 was <2 kg [1.7 kg (+/-4.5 SD) in the Americas trial and 1.4 kg (+/-3.6 SD) in the Europe/Asia trial]. In the SC/IM trial, mean weight changes were similar between DMPA-SC 104 and DMPA-IM 150 groups, with mean (+/-SD) gains at month 36 of 4.5+/-8.5 and 5.8+/-8.7 kg, respectively. Similar differences in weight gain were observed by age or baseline BMI in all studies. CONCLUSION:DMPA-SC 104 was associated with modest weight gain in most women.
RCT Entities:
INTRODUCTION: The study was conducted to assess the impact of depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL (DMPA-SC 104) on body weight. METHODS: Changes in weight from pretreatment were analyzed using data from two 1-year, noncomparative trials of DMPA-SC 104 (North/South American, N=722; European/Asian, N=1065) and a 3-year, randomized study (SC/IM) comparing DMPA-SC 104 (N=266) with the DMPA intramuscular injection 150 mg/mL (DMPA-IM 150). For each study, additional analyses were conducted for changes in body weight by age (<25, 25 to 35 and >35 years) and body mass index (BMI) (<or=25, >25 to <or=30 and >30 kg/m2) subgroups. RESULTS: In both 1-year trials, the mean (+/-SD) weight gain at month 12 was <2 kg [1.7 kg (+/-4.5 SD) in the Americas trial and 1.4 kg (+/-3.6 SD) in the Europe/Asia trial]. In the SC/IM trial, mean weight changes were similar between DMPA-SC 104 and DMPA-IM 150 groups, with mean (+/-SD) gains at month 36 of 4.5+/-8.5 and 5.8+/-8.7 kg, respectively. Similar differences in weight gain were observed by age or baseline BMI in all studies. CONCLUSION:DMPA-SC 104 was associated with modest weight gain in most women.
Authors: Hannah L H Lange; Martha A Belury; Michelle Secic; Alicia Thomas; Andrea E Bonny Journal: J Pediatr Adolesc Gynecol Date: 2014-05-05 Impact factor: 1.814
Authors: Laureen M Lopez; Alison Edelman; Mario Chen; Conrad Otterness; James Trussell; Frans M Helmerhorst Journal: Cochrane Database Syst Rev Date: 2013-07-02
Authors: Laureen M Lopez; Shanthi Ramesh; Mario Chen; Alison Edelman; Conrad Otterness; James Trussell; Frans M Helmerhorst Journal: Cochrane Database Syst Rev Date: 2016-08-28